IncobotulinumtoxinA for upper- and lower-limb spasticity in Japanese patients.

Current Medical Research and Opinion
Hitoshi KagayaRyuji Kaji

Abstract

Introduction: The safety and tolerability of incobotulinumtoxinA 400 U for upper- and lower-limb post-stroke spasticity was assessed in a small cohort of Japanese patients during the open-label lead-in tolerability periods (LITP) of two phase 3 studies (CTI-153029 and CTI-153030; Japan Pharmaceutical Information Centre).Methods: Adult patients received a single incobotulinumtoxinA injection session (total dose of 400 U) in the upper (J-PURE) or lower limb (J-PLUS). Adverse events (AEs) were assessed at 1, 4, 8 and 12 weeks post-injection during the 12 week follow-up.Results: The LITP of J-PURE and J-PLUS included 11 patients each. Mild/moderate AEs were reported by 5/11 (45.5%) and 8/11 (72.7%) patients in J-PURE and J-PLUS, respectively. No serious AEs were reported. Non-serious, transient AEs of special interest reported by two patients in J-PURE comprised muscular weakness and eyelid ptosis. No patient discontinued due to AEs.Conclusion: Preliminary results in this small population suggest that incobotulinumtoxinA 400 U is well tolerated for treating upper- or lower-limb post-stroke spasticity in Japanese patients.

References

Aug 27, 2002·Clinical Rehabilitation·C L WatkinsA K Sharma
Jul 5, 2003·Stroke; a Journal of Cerebral Circulation·M J AriesenA Algra
Dec 20, 2003·Stroke; a Journal of Cerebral Circulation·Disa K SommerfeldMagnus H von Arbin
Jun 8, 2004·Clinical Rehabilitation·M J LeathleyC L Watkins
Jun 17, 2005·Journal of Neural Transmission·P RoggenkämperUNKNOWN NT 201 Blepharospasm Study Team
Aug 30, 2008·Lancet Neurology·Mathew J ReevesLynda Lisabeth
Feb 7, 2009·Journal of Rehabilitation Medicine·Jörg WisselNiko Tieranta
Feb 13, 2009·Stroke; a Journal of Cerebral Circulation·Rodica E PetreaPhilip A Wolf
Aug 1, 2009·Clinical Neuropharmacology·Petr KanovskýSusanne Grafe
Apr 2, 2010·Journal of Neurology·Ryuji KajiUNKNOWN GSK1358820 Spasticity Study Group
May 13, 2010·Journal of Rehabilitation Medicine·Erik LundströmJörgen Borg
Jun 24, 2010·Current Medical Research and Opinion·Ryuji KajiUNKNOWN GSK1358820 Spasticity Study Group
Jul 17, 2010·European Journal of Neurology : the Official Journal of the European Federation of Neurological Societies·A EsquenaziA B Ward
Jan 18, 2013·Neurology·Jörg WisselMichael Brainin
Jan 23, 2014·Lancet·Valery L FeiginUNKNOWN Global Burden of Diseases, Injuries, and Risk Factors Study 2010 (GBD 2010) and the GBD Stroke Experts Group
Mar 11, 2015·Neurology·Ryuji Kaji
Jul 24, 2015·Muscle & Nerve·Elie Paul ElovicChristina Marciniak
Mar 12, 2017·Neurology·Jörg WisselUNKNOWN TOWER study investigators

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.